Market Access News | pharmaphorum

News

Regeneron tries again with lymphoma bispecific in US

Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.

News

Vaccine sector on edge as HHS cancels flu meeting

An FDA advisory committee due to be held in March to discuss the formulation of influenza vaccines for the 2025/26 flu season has been cancelled.

News

Lilly unveils $27bn reshoring drive around four new plants

Trump threatened tariffs if businesses do not reshore production to the US - and Lilly has now revealed a $27bn spend on new domestic facilities.

News

Can Keytruda finally break into early head and neck cancer?

The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

FDA clears first therapy for rare disease CTX from Mirum

Mirum Pharma's Ctexli has become the first FDA-approved therapy for ultra-rare disease cerebrotendinous xanthomatosis (CTX).

Regeneron tries again with lymphoma bispecific in US

Vaccine sector on edge as HHS cancels flu meeting

Lilly unveils $27bn reshoring drive around four new plants

Can Keytruda finally break into early head and neck cancer?

Lilly launches discounted high-strength Zepbound vials in US

FDA clears first therapy for rare disease CTX from Mirum

Nuvalent buy delivers new cancer approval for GSK

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks